BU-NOT-SET

CONTACT US
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
  • Drug product
Two lab workers
Case study
Recipharm Wins two 2020 CMO Leadership Awards
  • Industry trends
Eyes
Insight
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
  • Corporate
Eyes
Insight
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
API product list
  • Drug substance
white pills
Fact sheet
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
Insight
  • Drug product
The advantages of modified release oral dosage forms
Insight
  • Drug substance
Streamlining scale-up for drug substances
Insight
  • Drug product
Oral solids endure and evolve
Insight
  • Drug product
Patient-centric drug development comes of age
Insight
  • Manufacturing
Looking beyond the deadline
Insight
  • Drug product
Modified release formulations: improving efficacy and patient compliance
Insight
  • Manufacturing
FMD: industry thoughts as serialisation deadline nears
Report
  • Sustainability
Sustainability report 2019
Insight
  • Drug product
  • Drug substance
Sweden’s strong contract services market